Because elevated RALA expression was associated with poor outcome and treatment response in HER2+ BC patients (Figure 1), we also explored the impact of RAL knockdown upon in vivo and in vitro growth of the HER2+ cell line SKBR3. The gene discussed is RALA; the disease is breast cancer.